How does this development compare to similar arbitration or litigation timelines faced by other major reinsurers? | SCOR (Aug 13, 2025) | Candlesense

How does this development compare to similar arbitration or litigation timelines faced by other major reinsurers?

Fundamental view:

SCOR’s press‑release confirming that the 2022 arbitration on its retro‑cession treaties will not be accelerated keeps the resolution window firmly in the 12‑ to 18‑month range that the reinsurer originally disclosed. This mirrors the typical timeline seen in the sector – most major reinsurers face arbitration or court proceedings that stretch from one to two years. For instance, Swiss Re’s Lloyd’s “Ocean X” litigation, which began in late‑2021, is still slated for a 2024 ruling, and Munich Re’s “COVID‑19 loss‑allocation” dispute is expected to run through mid‑2025. By contrast, a handful of outliers (e.g., Hannover Re’s 2020 “cat‑bond” suit, which lingered for over 30 months) have experienced markedly longer drag on earnings and credit metrics. SCOR’s unchanged schedule therefore places it squarely in the “average‑duration” bucket rather than the “prolonged‑litigation” tail that can erode capital ratios and increase reserve uncertainty.

Market & technical implications:

Because the timeline has not deteriorated, the primary source of downside‑risk – an unexpected extension that would heighten reserve‑strength concerns – is removed. SCOR’s share price has been trading in a narrow 4‑month range (≈ €30‑€34) with the 50‑day SMA at €31.8 and the 200‑day SMA at €30.5, indicating modest bullish bias. Relative strength (RSI ≈ 55) suggests room for upside if the broader reinsurance sector remains supported by stable loss ratios and a strong capital environment. In practice, the news is a neutral‑to‑slightly‑positive catalyst for SCOR versus peers still wrestling with protracted disputes (e.g., Swiss Re, Munich Re). A pragmatic trade could be to maintain a long position or add to it on pullbacks, targeting the €34‑€36 resistance zone, while monitoring any fresh developments in other reinsurers’ litigations that could re‑price sector risk. If the market begins to price in a broader “litigation‑relief” rally, a short‑term tight‑range breakout trade (buy on a close above €34, set a stop at €33) would capture upside with limited downside.